Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $50.0833.
Several research analysts have weighed in on the company. Morgan Stanley increased their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an "overweight" rating in a research report on Thursday, June 25th. Citizens Jmp reduced their target price on shares of Pharvaris from $75.00 to $74.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 13th. UBS Group set a $74.00 price target on shares of Pharvaris in a research note on Wednesday, May 13th. Wall Street Zen lowered shares of Pharvaris from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th.
Read Our Latest Stock Report on Pharvaris
Insider Activity
In related news, Director Elisabeth Bjork sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total value of $293,200.00. Following the completion of the sale, the director directly owned 15,167 shares in the company, valued at approximately $444,696.44. The trade was a 39.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Wim Souverijns sold 10,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $29.92, for a total value of $299,200.00. Following the sale, the insider directly owned 45,111 shares in the company, valued at $1,349,721.12. This represents a 18.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 178,322 shares of company stock worth $5,969,286.
Hedge Funds Weigh In On Pharvaris
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. BlackRock Inc. bought a new stake in shares of Pharvaris during the 2nd quarter valued at $26,677,000. Deutsche Bank AG acquired a new stake in shares of Pharvaris during the 2nd quarter worth $1,849,000. Persistent Asset Partners Ltd bought a new position in shares of Pharvaris in the second quarter worth $273,000. GSA Capital Partners LLP bought a new position in shares of Pharvaris in the second quarter worth $558,000. Finally, CoreCap Advisors LLC acquired a new position in Pharvaris in the second quarter valued at about $93,000.
Pharvaris Stock Performance
Pharvaris stock opened at $34.91 on Monday. Pharvaris has a 12 month low of $19.56 and a 12 month high of $36.60. The stock's 50 day moving average is $33.24 and its 200-day moving average is $29.85. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -10.98 and a beta of -2.31.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. As a group, equities research analysts predict that Pharvaris will post -2.97 earnings per share for the current fiscal year.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
